MX2023005908A - Metodos para usar 4-amino-n-[4-(metoximetil)fenil]-7-(1- metilciclopropil)-6-(3-morfolinoprop-1-in-1-il)-7h-pirrolo[2,3- d]pirimidina-5-carboxamida para el tratamiento de tumores. - Google Patents

Metodos para usar 4-amino-n-[4-(metoximetil)fenil]-7-(1- metilciclopropil)-6-(3-morfolinoprop-1-in-1-il)-7h-pirrolo[2,3- d]pirimidina-5-carboxamida para el tratamiento de tumores.

Info

Publication number
MX2023005908A
MX2023005908A MX2023005908A MX2023005908A MX2023005908A MX 2023005908 A MX2023005908 A MX 2023005908A MX 2023005908 A MX2023005908 A MX 2023005908A MX 2023005908 A MX2023005908 A MX 2023005908A MX 2023005908 A MX2023005908 A MX 2023005908A
Authority
MX
Mexico
Prior art keywords
methods
morpholinoprop
yclopropyl
methylc
pyrrolo
Prior art date
Application number
MX2023005908A
Other languages
English (en)
Inventor
Claudio Giuliano
Emanuela Lovati
Ruben Giorgino
Isao Miyazaki
Masanori Kato
Simona Doria
Annalisa Bonifacio
Miharu Igarashi
Alberto Bernareggi
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of MX2023005908A publication Critical patent/MX2023005908A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona a composiciones y métodos para tratar pacientes con cáncer que tienen una anormalidad del gen RET que comprenden administrar HM06/TAS0953, por ejemplo pacientes con cáncer de pulmón de célula no pequeña (NSCLC), y que también puede tener metástasis de cerebro y/o leptomeníngea, u otro tumor sólido; donde el paciente se administra con una cantidad efectiva de HM06/TAS0953, donde el HM06/TAS0953 se puede formular en una composición y administrar oralmente en una sola o múltiples dosis; y donde los pacientes pueden haber recibido previamente y/o tener resistencia desarrollada a otro inhibidor selectivo de RET o de multi-quinasa.
MX2023005908A 2020-11-20 2021-11-18 Metodos para usar 4-amino-n-[4-(metoximetil)fenil]-7-(1- metilciclopropil)-6-(3-morfolinoprop-1-in-1-il)-7h-pirrolo[2,3- d]pirimidina-5-carboxamida para el tratamiento de tumores. MX2023005908A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063116282P 2020-11-20 2020-11-20
US202163229626P 2021-08-05 2021-08-05
PCT/EP2021/082120 WO2022106529A1 (en) 2020-11-20 2021-11-18 Methods of using 4-amino-n-[4-(methoxymethyl)phenyl]-7-(1-methylcyclopropyl)-6-(3-morpholinoprop-1-yn-1-yl)-7h-pyrrolo[2,3-d]pyrimidine-5-carboxamide for the treatment of tumors

Publications (1)

Publication Number Publication Date
MX2023005908A true MX2023005908A (es) 2023-07-17

Family

ID=78819834

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005908A MX2023005908A (es) 2020-11-20 2021-11-18 Metodos para usar 4-amino-n-[4-(metoximetil)fenil]-7-(1- metilciclopropil)-6-(3-morfolinoprop-1-in-1-il)-7h-pirrolo[2,3- d]pirimidina-5-carboxamida para el tratamiento de tumores.

Country Status (10)

Country Link
US (1) US20240000791A1 (es)
EP (1) EP4247379A1 (es)
JP (1) JP2024500628A (es)
KR (1) KR20230110557A (es)
AU (1) AU2021382896A1 (es)
CA (1) CA3201329A1 (es)
IL (1) IL302441A (es)
MX (1) MX2023005908A (es)
TW (1) TW202237129A (es)
WO (1) WO2022106529A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL261107B2 (en) * 2016-02-23 2023-11-01 Taiho Pharmaceutical Co Ltd A novel compressed pyrimidine compound or a salt thereof
TW201915027A (zh) * 2017-08-21 2019-04-16 日商大鵬藥品工業股份有限公司 Dctn1蛋白質與ret蛋白質之融合蛋白質
JP7060694B2 (ja) * 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物

Also Published As

Publication number Publication date
WO2022106529A1 (en) 2022-05-27
US20240000791A1 (en) 2024-01-04
CA3201329A1 (en) 2022-05-27
EP4247379A1 (en) 2023-09-27
JP2024500628A (ja) 2024-01-10
IL302441A (en) 2023-06-01
TW202237129A (zh) 2022-10-01
AU2021382896A1 (en) 2023-05-25
KR20230110557A (ko) 2023-07-24

Similar Documents

Publication Publication Date Title
EP3066101B1 (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
JP4729503B2 (ja) 抗癌剤の奏効率増強剤
EP1971338B1 (en) Combination of zd6474 and pemetrexed
WO2017200016A1 (ja) Ｅｇｆｒ－ｔｋｉ耐性を獲得した肺癌の治療薬
Liu et al. β-elemene enhances both radiosensitivity and chemosensitivity of glioblastoma cells through the inhibition of the ATM signaling pathway
NO20066056L (no) Behandling med Gemcitabin og en EGFR-inhibitor
JP2008501630A6 (ja) 抗癌剤の効果増強剤
MX2022010128A (es) Compuestos macrocíclicos y usos de estos.
Cheng et al. Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib
WO2021108672A1 (en) Combination therapy involving diaryl macrocyclic compounds
TW200603804A (en) Treatment with irinotecan (cpt-11) and an EGFR-inhibitor
Zhang et al. Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma
CN112386593A (zh) 一种含西达本胺的抗肿瘤药物组合物及其应用
TW200608959A (en) Treatment with oxaliplatin and an egfr-inhibitor
JP2016515619A (ja) カルボキシアミドトリアゾールオロテートを使用する、先の化学療法薬および標的薬物に対する獲得耐性を持つ癌を治療するための方法および組成物
Misset et al. Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors
Papac et al. Hormonal therapy for metastatic renal cell carcinoma combined androgen and provera followed by high dose tamoxifen
MX2023005908A (es) Metodos para usar 4-amino-n-[4-(metoximetil)fenil]-7-(1- metilciclopropil)-6-(3-morfolinoprop-1-in-1-il)-7h-pirrolo[2,3- d]pirimidina-5-carboxamida para el tratamiento de tumores.
JP2021526161A (ja) 癌治療のための方法及び医薬組成物
El-Khoueiry et al. Leveraging innate immunity with AFM24, a novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager: Interim results for the non-small cell lung cancer (NSCLC) cohort
Han et al. P2. 01-21 efficacy and safety of combing anlotinib and erlotinib as a first-line therapy in patients with advanced non-small cell lung cancer (NSCLC)
Benitez et al. Hepatic intra-arterial chemotherapy with immunotherapy in NSCLC
Chen et al. Current status of clinical studies for colorectal cancer in Taiwan
Yang et al. Successful Treatment of a Miliary Metastatic NSCLC Patient With Activating EGFR Exon 20 Insertion Mutation with Response to Poziotinib
JPWO2019196764A5 (es)